Profile of panobinostat and its potential for treatment in solid tumors: an update

The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobino...

Descripción completa

Detalles Bibliográficos
Autores principales: Anne, Madhurima, Sammartino, Daniel, Barginear, Myra F, Budman, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833618/
https://www.ncbi.nlm.nih.gov/pubmed/24265556
http://dx.doi.org/10.2147/OTT.S30773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833618/
https://www.ncbi.nlm.nih.gov/pubmed/24265556
http://dx.doi.org/10.2147/OTT.S30773

Ejemplares similares